The Vision Lab Choice Act of 2025 inserts a new section (2719B) into Title XXVII of the Public Health Service Act governing vision benefits. It imposes rules on agreements between vision plans and doctors of optometry—shortening initial contract terms, conditioning extensions on provider acceptance, and barring plans from restricting the optometrist’s choice of laboratories, sources, or suppliers.
The bill also creates an annual HHS notification to states about enforcement responsibility and includes a conforming amendment and an explicit clause preserving state-law primacy where state rules conflict with the new federal text. Practically, the measure shifts how vision benefit plans negotiate with optometrists and places enforcement pressure on states while protecting provider autonomy over supply chains.
At a Glance
What It Does
The bill adds section 2719B to the Public Health Service Act to regulate provider agreements in vision benefit plans: it caps the length of initial agreements, requires provider consent for extensions, prohibits any plan-imposed restrictions on an optometrist’s choice of labs or suppliers, and directs HHS to query states annually about enforcement. It also amends 2722(c)(1) and preserves state law where conflicts exist.
Who It Affects
Applies to group health plans and individual or group insurance coverage that include vision benefits, including limited‑scope vision plans. Primary operational impacts fall on health insurance issuers and third‑party administrators that negotiate provider agreements, doctors of optometry and their practices, and laboratories and suppliers serving optometrists.
Why It Matters
The bill limits a common network control tactic—contractual restrictions on lab and supply choice—and forces shorter, optometrist‑consented contract cycles. That changes negotiation leverage between insurers and optometrists, could alter procurement and quality-control practices, and pushes states to decide whether to police compliance or cede enforcement consequences to the federal government.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Act creates a dedicated federal rule for vision benefit relationships by inserting a new section—2719B—into the Public Health Service Act. Under that section, any health plan or insurance product that offers vision benefits falls within the rule’s scope, including products that are narrowly tailored to vision services.
The law focuses on two provider protections: limits on how long an insurer can bind an optometrist in a contract without renewal and a flat prohibition on plan clauses that narrow an optometrist’s choice of laboratories or suppliers.
Operationally, the bill sets a maximum for the initial term of a vision agreement and ties any extensions to the optometrist’s prior acceptance; however, it allows those extensions to repeat indefinitely if the provider agrees each time. The prohibition on restricting choice is broad: plans may not directly or indirectly limit which laboratory or vendor a doctor uses when providing materials or services to an enrolled patient.
The text defines “doctor of optometry” by reference to the State authorization where the doctor practices.To drive compliance, the Secretary of Health and Human Services must annually notify each State asking whether the State will enforce the new requirements. A State has 90 days to respond; a nonresponse or an explicit refusal leads the Secretary to treat the State as failing to “substantially enforce” the provisions for purposes of cross‑references to section 2723 in the Act—a procedural step that activates federal oversight mechanisms tied to that statutory scheme.
The bill also includes a narrow conforming edit to section 2722(c)(1) and an express clause saying State law that directly regulates health insurers and vision benefit plans remains in force where it conflicts with the amendments, leaving primary regulatory authority with the States in such conflicts.
The Five Things You Need to Know
The bill caps the initial term of an agreement between a group health plan (or insurer) and a doctor of optometry at 2 years.
Each contract extension requires the optometrist’s prior acceptance; any single extension may not exceed 2 years but the parties may agree to unlimited sequential extensions.
Health plans and issuers may not, directly or indirectly, restrict an optometrist’s choice of laboratories or suppliers for services or materials provided to enrolled patients.
HHS must notify each State annually and ask whether the State will enforce the new rules; States have 90 days to respond, and a nonresponse is treated as failing to substantially enforce for purposes of section 2723.
The bill amends section 2722(c)(1) (adding a parenthetical excluding requirements under new section 2719B) and separately states that conflicting State law continues to apply and that States retain exclusive jurisdiction over issuers and limited‑scope vision plans governed by State law.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Designates the measure as the “Vision Lab Choice Act of 2025.” This is nominal but important for citation and references in regulatory or enforcement materials.
New federal standard for vision plan‑optometrist agreements
Adds section 2719B to Title XXVII. Subsection (a) sets the scope—applying to group health plans and individual or group insurance coverage that provides vision care, including limited‑scope vision benefits. This is the operative text that creates the contract‑term limits and the ban on restrictions of an optometrist’s choice of labs, sources, or suppliers. Practically, carriers writing vision benefits must examine plan documents and provider agreements to remove or change forbidden clauses.
Two‑year initial term and conditional extensions
Specifies that for optometrists with agreements under such plans the initial agreement cannot exceed two years. Any extension must be preceded by the doctor’s acceptance; each extension itself may be no longer than two years, and the parties may continue to agree to extensions indefinitely. That language limits unilateral multi‑year locks while preserving rolling renewal as a negotiation tool.
Prohibition on plan restrictions of laboratory/supplier choice
Prohibits a plan or issuer from directly or indirectly restricting which laboratories, sources, or suppliers an optometrist may use to provide services or materials to enrolled patients. The ban reaches contractual clauses and likely administrative practices that function as de facto restrictions, requiring plans to remove written controls that narrow provider procurement choices.
State notification, enforcement consequences, definition, and state‑law carve‑out
Subsection (b) directs HHS to notify States annually about their authority to enforce subsection (a) and to request confirmation whether the State will enforce it; lack of response within 90 days or an affirmation of non‑enforcement lets the Secretary treat the State as failing to substantially enforce the provisions for purposes of specified parts of section 2723. Subsection (c) defines ‘doctor of optometry’ as a practitioner legally authorized in the State where they practice. The bill also amends section 2722(c)(1) to insert a parenthetical excluding requirements under new section 2719B, and separately asserts that State law taking direct effect over insurers and vision plans remains exclusive where there is a conflict with this Act, preserving state regulatory primacy in such cases.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Doctors of optometry — Gains negotiation leverage and procurement autonomy because initial contract lengths are capped and extensions require prior provider acceptance, and plans may not dictate lab/supplier choices.
- Independent and specialty laboratories/suppliers — Reduced risk of being shut out by network clauses; greater ability to compete for optometrist business when plans cannot mandate a single vendor.
- Patients receiving vision services — Potentially broader access to varied product lines, custom lenses, and suppliers chosen by their treating optometrist rather than a plan’s preferred vendor.
Who Bears the Cost
- Health insurance issuers and plan sponsors — Must revise provider contracts and network rules, remove restrictive procurement clauses, and potentially face higher supply costs or administrative adjustments.
- Third‑party administrators and managed vision networks — Losing a leverage point (vendor exclusivity) that they use to control cost and standardize delivery could increase operational complexity.
- State regulators and HHS — The bill forces annual decision points for states (enforce or not) and could generate administrative and legal work if many states decline enforcement and federal backstop mechanisms are invoked.
Key Issues
The Core Tension
The central tension is between provider autonomy and supply‑chain choice on one hand, and insurers’ need to manage networks, quality control, and costs on the other. The bill protects optometrists from long‑term contractual lock‑ins and supplier mandates, but in doing so it removes a cost‑management tool insurers use to standardize care and negotiate price—forcing a trade‑off between professional independence and mechanisms that can restrain premiums and streamline operations.
The bill’s text is compact but creates several practical and legal fault lines. First, the ban on restrictions is broad in language but thin on definitional guidance: it bars direct or indirect restrictions on choice of laboratories or suppliers, but does not define ‘indirect’ or distinguish between contractual prohibitions and financial incentives (for example, higher reimbursements for plan‑preferred vendors).
That gap leaves room for carriers to redesign network economics in ways that preserve functional control without explicit contractual bars.
Second, the enforcement mechanism hinges on State action. HHS will annually ask whether each State will enforce the rule and will treat nonresponses or refusals as a failure to substantially enforce for purposes tied to section 2723.
The bill does not itself spell out the downstream remedies HHS will deploy following that finding, creating uncertainty about timing, scope of federal intervention, and legal exposure for plans operating across states. Finally, the separate clause preserving State law where it conflicts with the federal amendment creates a patchwork risk: carriers operating in multiple states may face divergent rules, and the interaction between this federal baseline and existing state statutes or regulations (some of which already authorize plan‑imposed procurement rules) will create litigation and compliance burdens as parties test which rules govern in each jurisdiction.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.